Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2017

Yao Yung-Mae M, Donoho Gregory P, Iversen Philip W, Zhang Youyan, Van Horn Robert D, Forest Amelie, Novosiadly Ruslan D, Webster Yue Wang, Ebert Philip, Bray Steven, Ting Jason C, Aggarwal Amit, Henry James R, Tiu Ramon V, Plowman Gregory D, Peng Sheng-Bin

Abstract excerpt

Purpose: To evaluate the antitumor efficacy of cetuximab in combination with LSN3074753, an analog of LY3009120 and pan-RAF inhibitor in 79 colorectal cancer patient-derived xenograft (PDX) models.Experimental Design: Seventy-nine well-characterized colorectal cancer PDX models were employed to conduct a single mouse per treatment group (n = 1) trial.Results: Consistent with clinical results, cetuximab was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ligands

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins B-raf

Share to Pyrimidines

Share to Survival Rate

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28611205
DOI: 10.1158/1078-0432.CCR-16-3250

Genes

BRAF
KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.PMID 28611205Read ↗

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.Semantic proximity Read ↗

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.Semantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer.Semantic proximity Read ↗

Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?Semantic proximity Read ↗

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.Semantic proximity Read ↗

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.Semantic proximity Read ↗

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.Semantic proximity Read ↗

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.Semantic proximity Read ↗

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.Semantic proximity Read ↗

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.